SCPS:OTC-Scopus Biopharma Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.0011

Change

0.00 (0.00)%

Market Cap

USD 0.07M

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

+1.48 (+1.10%)

USD 599.53B
CSLLY CSL Ltd

-0.06 (-0.06%)

USD 90.20B
CMXHF CSL Limited

+2.45 (+1.35%)

USD 90.20B
UCBJF UCB SA

N/A

USD 26.60B
UCBJY UCB SA ADR

-0.60 (-0.86%)

USD 26.44B
ARGNF argenx SE

N/A

USD 22.20B
GNMSF Genmab A/S

+20.24 (+7.50%)

USD 18.02B
WXIBF WuXi Biologics

-0.24 (-13.86%)

USD 7.05B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.91B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 6.91B

ETFs Containing SCPS

IEO 18.96 % 0.42 %

N/A

N/A
NRGO 10.00 % 0.00 %

N/A

N/A
NRGZ 10.00 % 0.00 %

N/A

N/A
YGRN 10.00 % 0.00 %

N/A

N/A
FRAK 8.73 % 0.54 %

N/A

N/A
XLE Energy Select Sector SPDR.. 8.64 % 0.13 %

+0.94 (+0%)

USD 39.74B
VDE Vanguard Energy Index Fun.. 7.23 % 0.10 %

+1.46 (+0%)

USD 8.98B
JHME 6.90 % 0.48 %

N/A

N/A
NXF:CA First Asset Energy Giants.. 6.62 % 0.72 %

N/A

CAD 0.16B
DDG 5.83 % 0.95 %

N/A

N/A
DUG ProShares UltraShort Oil .. 5.83 % 0.95 %

-0.20 (0%)

USD 0.02B
ERYY 4.79 % 0.45 %

N/A

N/A
HUL-U:CA 4.46 % 0.00 %

N/A

N/A
HUL:CA 4.46 % 2.20 %

N/A

N/A
GASX 4.29 % 1.01 %

N/A

N/A
QUAL 2.23 % 0.15 %

N/A

N/A
GASL 1.45 % 1.19 %

N/A

N/A
TERM 0.88 % 0.64 %

N/A

N/A
BWX SPDR® Bloomberg Internat.. 0.00 % 0.50 %

-0.08 (0%)

USD 0.88B
EBND SPDR® Bloomberg Emerging.. 0.00 % 0.41 %

-0.01 (0%)

USD 1.98B
EQWL Invesco S&P 100 Equal Wei.. 0.00 % 0.25 %

-0.46 (0%)

USD 0.66B
MTUM 0.00 % 0.15 %

N/A

N/A
TGED:CA TD Active Global Enhanced.. 0.00 % 0.00 %

-0.04 (0%)

CAD 0.27B
RYE 0.00 % 0.40 %

N/A

N/A
WIP SPDR® FTSE International.. 0.00 % 0.50 %

-0.28 (0%)

USD 0.40B
HPF:CA Energy Leaders Plus Incom.. 0.00 % 1.74 %

+0.04 (+0%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -97.44% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.44% 3% F 1% F
Trailing 12 Months  
Capital Gain -98.17% 5% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.17% 5% F 3% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -62.69% 1% F N/A F
Dividend Return -62.69% 1% F N/A F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 41.17% 70% C- 57% F
Risk Adjusted Return -152.28% 2% F 1% F
Market Capitalization 0.07M 16% F 10% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.